
A multivalent mRNA influenza vaccine for broad immunity to seasonal and pandemic influenza in animal models
Researchers from Duke CIVIC Vaccine Center (DCVC) developed an mRNA-lipid nanoparticle vaccine incorporating hemagglutinin antigens from 20 different influenza subtypes.